In this Director’s message, Dr. Gordon discusses the role of NIMH and other researchers in the development of esketamine, an FDA-approved, rapid-acting medication that targets treatment-resistant depression.
| Read the Director's Message |
International Journal for Equity in Health
Hace 6 horas
No hay comentarios:
Publicar un comentario